PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Sagar Lonial, MD, FACP / Praneetha Thulasi, MD - Targeting Ocular Toxicity in Multiple Myeloma: Opportunities for Ophthalmology-Oncology Collaboration
Go online to PeerView.com/DMW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts, an oncologist and ophthalmologist, discuss the intricacies of ocular toxicities associated with multiple myeloma and explore the importance of collaborating when managing patients who are being treated with novel therapeutics. Upon completion of this activity, participants should be better able to: Identify ocular complications associated with the use of novel therapeutic options in the myeloma treatment setting, Utilize management tools such as dry eye prophylaxis, routine eye examinations, and therapeutic dose adjustment to address ocular toxicity in patients with myeloma, Develop strategies for oncology-ophthalmology collaboration in monitoring for and managing ocular toxicity in myeloma patients.
George L. Bakris, MD - Improving Outcomes and Preventing Chronic Kidney Disease Progression: Evaluating the Role of Novel Nonsteroidal Mineralocorticoid Receptor Antagonists
Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.
Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?
Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.
Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach
Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK inhibitor, selumetinib, approved for pediatric patients who have this debilitating rare disease. This on-demand activity provides expert insights into the pathophysiology of NF1, its clinical presentation, and practical guidance for management. In addition, the mechanistic rationale and latest evidence supporting the use of currently approved and emerging targeted therapies for NF1 are presented. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas (PNs) and other NF1-associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF1-related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF1-related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF1-related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.
Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure
Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Describe the prevalence of ID in patients with HF and its impact on patient outcomes and quality of life, Interpret laboratory results for diagnosing and monitoring iron status in patients with HF, Apply current clinical guidelines and clinical trial results for iron therapies to improve outcomes in patients with ID and HF.
Sean Pokorney, MD, MBA - Improving Recognition of Nonvalvular Atrial Fibrillation to Reduce the Risk of Preventable Stroke: A Visual Guide for Clinicians
Go online to PeerView.com/PFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, cardiologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with or at risk for NVAF. Upon completion of this activity, participants should be better able to: Employ various evidence-based screening methods to identify patients with undiagnosed NVAF, Engage in shared decision-making with patients with NVAF about the benefits and limitations of anticoagulant therapies to reduce the risk of stroke in the context of anticoagulation stewardship.